Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6407221

Title:Chimeric chains for receptor-associated signal transduction pathways
Inventors:Capon, Daniel J.; Hillsborough, CA, USA
Summary:Described herein is a novel chimeric protein with a non-major histocompatability complex, a restricted extracellular binding domain, a transmembrane domain, and a cytoplasmic signal-transducing domain. The invention relates to chimeric proteins and DNA encoding the chimeric proteins, in which the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner. Further disclosed are properties of a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. Claims of the invention include the binding of a ligand to the extracellular domain, resulting in the transduction of a signal and the activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signaling pathway. Therapeutic applications in signal transduction are provided.
Abstract:Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6407221
Application Number:US1995000475442
Date Filed:07/06/1995
Date Published:18/06/2002
Assignee:Cell Genesys, Inc., Foster City, CA, USA Regents of the University of California, Oakland, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/10/2020